View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

M&As this week: Orion Biotechnology Canada, SOPHiA GENETICS, GI Partners

Orion Biotechnology Canada has completed the acquisition of K2Biomedical for an undisclosed sum.

Orion Biotechnology Canada has completed the acquisition of K2Biomedical for an undisclosed sum.

K2Biomedical will operate as Orion Biotechnology Poland, following the acquisition. It will be located in the Jagiellonian Centre of Innovation in Krakow, Poland, and will be engaged in the development of novel technologies and new drugs for the international market.

Based in Canada, Orion is a developer of new treatments for chronic diseases, while K2Biomedical is a Polish pharmaceutical research company specialising in the field of genomics, proteomics and pharmacology.

The transaction enables the acquirer company to expand its product portfolio developed for the treatment of oncology and neuro-inflammatory disorders.

SOPHiA GENETICS has purchased Interactive Biosoftware (IBS) for an undisclosed sum.

The acquisition will enable SOPHiA to use IBS’ decision support software, Alamut, for its clinical genomic data interpretation needs. It will also enable the company to support hospitals and patients with the latest technologies, as well as accelerate the global adoption of data-driven medicine.

“SOPHiA GENETICS has purchased Interactive Biosoftware (IBS) for an undisclosed sum.”

Based in Switzerland, SOPHiA GENETICS is a healthcare technology company and a developer of clinical genomics technology, SOPHiA Artificial Intelligence (AI), while IBS is a France-based company involved in the development of software solutions in the field of human genetics.

GI Partners has signed an agreement to purchase Cord Blood Registry (CBR Systems) from AMAG Pharmaceuticals, a biopharmaceutical company, for $530m in cash.

Simultaneously, the company announced plans to purchase California Cryobank (CCB) from healthcare investors, Longitude Capital and NovaQuest Capital, for an undisclosed sum.

CBR and California Cryobank will work under a combined entity named California Cryobank Life Sciences.

The transaction is expected to be closed in the third quarter of this year and is subject to customary closing conditions.

GI is a private investment company, while California Cryobank is a donor egg bank, and CBR is a stem cell storage company.

All companies involved in the transaction are based in the US.

The transaction will enable the acquirer company to expand the capabilities of the new combined entity.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena